These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

580 related items for PubMed ID: 29423715

  • 1. Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker.
    Mori Y, Kasai H, Ose A, Serada M, Ishiguro M, Shiraki M, Tanigawara Y.
    Osteoporos Int; 2018 May; 29(5):1155-1163. PubMed ID: 29423715
    [Abstract] [Full Text] [Related]

  • 2. Prediction of Fracture Risk From Early-Stage Bone Markers in Patients With Osteoporosis Treated With Once-Yearly Administered Zoledronic Acid.
    Kasai H, Mori Y, Ose A, Shiraki M, Tanigawara Y.
    J Clin Pharmacol; 2021 May; 61(5):606-613. PubMed ID: 33135182
    [Abstract] [Full Text] [Related]

  • 3. Further significant effects of eldecalcitol on bone resorption markers and bone mineral density in postmenopausal osteoporosis patients having undergone long-term bisphosphonate treatment.
    Iba K, Sonoda T, Takada J, Dohke T, Yamashita T.
    J Bone Miner Metab; 2017 Mar; 35(2):171-176. PubMed ID: 26832388
    [Abstract] [Full Text] [Related]

  • 4. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide.
    Tähtelä R, Seppänen J, Laitinen K, Katajamäki A, Risteli J, Välimäki MJ.
    Osteoporos Int; 2005 Sep; 16(9):1109-16. PubMed ID: 15605190
    [Abstract] [Full Text] [Related]

  • 5. Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment.
    Kondo H, Okimoto N, Yoshioka T, Akahoshi S, Fuse Y, Ogawa T, Okazaki Y, Katae Y, Tsukamoto M, Yamanaka Y, Kawasaki M, Sakai A.
    J Bone Miner Metab; 2020 Nov; 38(6):894-902. PubMed ID: 32656645
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the Efficacy of Zoledronate Acid or Denosumab After Switching from Romosozumab in Japanese Postmenopausal Patients.
    Oue T, Shimizu T, Asano T, Shimodan S, Ishizu H, Arita K, Iwasaki N.
    Calcif Tissue Int; 2023 Jun; 112(6):683-690. PubMed ID: 37037949
    [Abstract] [Full Text] [Related]

  • 7. Effects of zoledronic acid on bone mineral density around prostheses and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis.
    Zhou W, Liu Y, Guo X, Yang H, Xu Y, Geng D.
    Osteoporos Int; 2019 Aug; 30(8):1581-1589. PubMed ID: 31115592
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of discontinuing risedronate for patients with systemic lupus erythematosus: a prospective study.
    Ishida T, Yoshida S, Kimura Y, Fujiki Y, Kotani T, Takeuchi T, Makino S, Arawaka S.
    Lupus; 2018 Sep; 27(10):1636-1643. PubMed ID: 29954283
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
    Roux C, Reid DM, Devogelaer JP, Saag K, Lau CS, Reginster JY, Papanastasiou P, Bucci-Rechtweg C, Su G, Sambrook PN.
    Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
    [Abstract] [Full Text] [Related]

  • 12. Vitamin D and Calcium Addition during Denosumab Therapy over a Period of Four Years Significantly Improves Lumbar Bone Mineral Density in Japanese Osteoporosis Patients.
    Suzuki T, Nakamura Y, Kato H.
    Nutrients; 2018 Feb 27; 10(3):. PubMed ID: 29495518
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The importance of assessing the rate of bone turnover and the balance between bone formation and bone resorption during daily teriparatide administration for osteoporosis: a pilot study.
    Nakatoh S.
    J Bone Miner Metab; 2016 Mar 27; 34(2):216-24. PubMed ID: 26031934
    [Abstract] [Full Text] [Related]

  • 15. Administration of Intravenous Zoledronic Acid Every 3 Months vs. Annually in β-thalassemia Patients with Low Bone Mineral Density: a Retrospective Comparison of Efficacy.
    Darvishi-Khezri H, Kosaryan M, Akbarzadeh R, Aliasgharian A, Fazli M.
    Med Arch; 2018 Jun 27; 72(3):170-173. PubMed ID: 30061760
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The Efficacy of Minodronate in the Treatment of Glucocorticoid-induced Osteoporosis.
    Hasegawa E, Ito S, Takai C, Kobayashi D, Nomura Y, Otani H, Abe A, Ishikawa H, Murasawa A, Narita I, Nakazono K.
    Intern Med; 2018 Aug 01; 57(15):2169-2178. PubMed ID: 29607978
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.